The Gut and Graves’ Disease: Why Researchers Are Excited

The gut and Graves’ Disease: key takeways

• The gut microbiome is one of the most exciting emerging areas of Graves’ disease research
• Research suggests people with Graves’ disease often have altered gut microbiome patterns compared with healthy individuals
• The gut microbiome may influence immune function and autoimmune activity in Graves’ disease
• Scientists are still trying to understand whether microbiome changes contribute to Graves’ disease, or whether Graves’ disease itself alters the microbiome
• Animal studies suggest the gut microbiome may play an active role in Graves’-like disease mechanisms
• Gut-targeted therapies are being explored as supportive add-on approaches, not as replacements for standard medical treatment
• There is currently no proof that “fixing” the microbiome cures Graves’ disease
• Current evidence most strongly supports broader gut health strategies such as fibre-rich diets, Mediterranean-style eating patterns, fermented foods, regular exercise, stress management, sleep optimisation, and avoiding smoking
• More large, high-quality human studies are still needed

What is Graves’ Disease and what happens in the body?

Graves’ disease is an autoimmune condition. In Graves’ disease, the immune system becomes dysregulated and mistakenly begins producing antibodies called TRAb (thyrotropin receptor antibodies), which target the thyroid’s TSH receptors. These antibodies act like false “on” signals, continuously stimulating the thyroid gland to produce excess thyroid hormones.

Normally, the brain carefully regulates thyroid hormone production through TSH signalling. In Graves’ disease, however, the autoimmune response overrides this system and causes the thyroid to become overactive (hyperthyroidism).

This speeds up many processes in the body and can lead to symptoms such as anxiety, palpitations, heat intolerance, tremor, insomnia, weight loss, and muscle weakness. Over time, autoimmune activity in Graves’ disease can vary – some people enter remission when antibody levels fall, while others experience relapses.

The gut and Graves’ disease: what we know so far

Together these studies indicate:

• People with Graves’ disease often have altered gut microbiome profiles
• The gut microbiome may be involved in immune dysregulation and autoimmune activity in Graves’ disease
• Certain bacteria may potentially influence inflammation, immune regulation, or TRAb persistence

A 2024 systematic review and meta-analysis broadly supported these findings, concluding that people with Graves’ disease often have altered gut microbiome profiles compared with healthy controls, although causation and clinical implications remain uncertain (Al-Kader et al., 2023).

Why researchers are excited

Researchers are now contemplating the following:

• The gut may play a role in why some people develop autoimmune thyroid disease
• Some gut bacteria may help keep the immune system calmer and more balanced
• Other bacterial patterns may potentially promote more inflammation or autoimmune activity
• Microbiome changes could affect TRAB antibody activity
• Probiotics or diet may one day help support standard Graves’ treatment
• Some scientists believe future microbiome-targeted therapies may eventually play a larger role in managing autoimmune thyroid disease, although current evidence is still preliminary and standard medical treatment remains essential.

For a deeper look at the dietary approaches studied in Graves’ disease, read: Can Graves’ Disease Be Treated with Diet? What the Research Says.

Also, I’ve broken down the full evidence for specific diet and lifestyle approaches in detail here: Diet and Lifestyle Approaches Studied in Graves’ Disease: What the Evidence Says.

References

Yan, H., et al. (2020) ‘Intestinal microbiota changes in Graves’ disease: a prospective clinical study’, Bioscience Reports, 40(9). Available at: https://doi.org/10.1042/BSR20191242.

Moshkelgosha, S., et al. (2021) ‘Modulating gut microbiota in a mouse model of Graves’ orbitopathy and its impact on induced disease’, Microbiome, 9(1). Available at: https://doi.org/10.1186/s40168-020-00952-4.

Jeong, C., et al. (2024) ‘Gut microbiome in Graves’ disease: Comparison before and after anti-thyroid drug treatment’, PLoS One, 19(5), e0300678. Available at: https://doi.org/10.1371/journal.pone.0300678.

Masetti, G. and Ludgate, M. (2020) ‘Microbiome and Graves’ Orbitopathy’, European Thyroid Journal, 9(Suppl. 1), pp. 78–86. Available at: https://doi.org/10.1159/000512255.

Al-Kader, D. A., et al. (2023) ‘Exploring the role of gut microbiota in autoimmune thyroid disorders: a systematic review and meta-analysis’, Frontiers in Endocrinology, 14. Available at: https://doi.org/10.3389/fendo.2023.1238146.

FAQ’s